We applied a mass spectrometry-based immunopeptidomics approach on primary multiple myeloma (MM) samples and MM cell lines, integrating whole-exome and RNA sequencing to comprehensively characterize the MM immunopeptidome and systematically search for TAAs and neoantigens.